Innova Therapeutics

Innova Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies for cancers with high unmet medical needs. The company specializes in targeting the Hippo signaling pathway, specifically through the inhibition of TEAD transcription factors. Its lead program, IVT-80, is a small molecule inhibitor currently being evaluated in Phase 1/2 clinical trials for patients with malignant mesothelioma and other solid tumors harboring NF2 mutations. Innova's approach leverages deep expertise in the Hippo-YAP/TAZ-TEAD axis to disrupt oncogenic signaling and provide new treatment options for oncology patients. The company aims to utilize precision medicine to identify patient populations most likely to benefit from its targeted therapies.